Similar articles for PMID: 29104462

Year	Number of Results
2001	2
2002	4
2004	3
2005	6
2006	6
2007	4
2008	3
2009	5
2010	8
2011	8
2012	9
2013	11
2014	20
2015	19
2016	7
2017	8
2018	2
2019	3
2020	2
2021	1
2022	1
2024	0

1

Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy.

Nakamoto S, Imazeki F, Kanda T, Wu S, Nakamura M, Yasui S, Tawada A, Mikata R, Chiba T, Arai M, Yokosuka O, Shirasawa H. Nakamoto S, et al. Int J Med Sci. 2017 Sep 4;14(11):1088-1093. doi: 10.7150/ijms.20171. eCollection 2017. Int J Med Sci. 2017. PMID: 29104462 Free PMC article.

2

Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.

Ishiguro H, Abe H, Seki N, Sugita T, Aida Y, Itagaki M, Sutoh S, Shimada N, Furihata T, Tsubota A, Aizawa Y. Ishiguro H, et al. World J Gastroenterol. 2015 Apr 7;21(13):3904-11. doi: 10.3748/wjg.v21.i13.3904. World J Gastroenterol. 2015. PMID: 25852275 Free PMC article.

3

A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection.

Chang KC, Tseng PL, Wu YY, Hung HC, Huang CM, Lu SN, Wang JH, Lee CM, Chen CH, Tsai MC, Yen YH, Lin MT, Wu CK, Huang CC, Chen HH, Hu TH. Chang KC, et al. Clin Gastroenterol Hepatol. 2015 May;13(5):1017-24. doi: 10.1016/j.cgh.2014.10.035. Epub 2014 Nov 13. Clin Gastroenterol Hepatol. 2015. PMID: 25460552

4

Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C.

Świątek-Kościelna B, Kałużna E, Strauss E, Nowak J, Bereszyńska I, Gowin E, Wysocki J, Rembowska J, Barcińska D, Mozer-Lisewska I, Januszkiewicz-Lewandowska D. Świątek-Kościelna B, et al. World J Gastroenterol. 2017 Jun 7;23(21):3815-3824. doi: 10.3748/wjg.v23.i21.3815. World J Gastroenterol. 2017. PMID: 28638221 Free PMC article.

5

Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.

Boglione L, Cardellino CS, Cusato J, De Nicolò A, Cariti G, Di Perri G, D'Avolio A. Boglione L, et al. Infect Genet Evol. 2017 Jul;51:167-172. doi: 10.1016/j.meegid.2017.03.014. Epub 2017 Mar 16. Infect Genet Evol. 2017. PMID: 28315743 Free article.

6

Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C.

Estrabaud E, Lapalus M, Broët P, Appourchaux K, De Muynck S, Lada O, Martinot-Peignoux M, Bièche I, Valla D, Bedossa P, Marcellin P, Vidaud M, Asselah T. Estrabaud E, et al. J Virol. 2014 Jun;88(11):6394-402. doi: 10.1128/JVI.00016-14. Epub 2014 Mar 26. J Virol. 2014. PMID: 24672032 Free PMC article.

7

IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.

Eslam M, Leung R, Romero-Gomez M, Mangia A, Irving WL, Sheridan D, Spengler U, Mollison L, Cheng W, Bugianesi E, McLeod D, Zaitoun AM, Attino V, Goeltz D, Nattermann J, Douglas M, Booth DR, George J, Ahlenstiel G. Eslam M, et al. J Hepatol. 2014 Aug;61(2):235-41. doi: 10.1016/j.jhep.2014.03.039. Epub 2014 Apr 24. J Hepatol. 2014. PMID: 24768758

8

Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b.

Hashimoto Y, Ochi H, Abe H, Hayashida Y, Tsuge M, Mitsui F, Hiraga N, Imamura M, Takahashi S, Nelson Hayes C, Ohishi W, Kubo M, Tsunoda T, Kamatani N, Nakamura Y, Chayama K. Hashimoto Y, et al. J Med Virol. 2011 Jun;83(6):981-8. doi: 10.1002/jmv.22028. J Med Virol. 2011. PMID: 21503910

9

Prevalence and impact of hepatic steatosis on the response to antiviral therapy in Saudi patients with genotypes 1 and 4 chronic hepatitis C.

AlQaraawi AM, Sanai FM, Al-Husseini H, Albenmousa A, AlSheikh A, Ahmed LR, Hersi A, Al-Otaibi MM, Syed M, Ali SM, Al-hamoudi W, Alswat KA, Abdo AA. AlQaraawi AM, et al. Dig Dis Sci. 2011 Apr;56(4):1222-8. doi: 10.1007/s10620-010-1417-9. Epub 2010 Oct 8. Dig Dis Sci. 2011. PMID: 20931285

10

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H. Akuta N, et al. Hepatology. 2010 Aug;52(2):421-9. doi: 10.1002/hep.23690. Hepatology. 2010. PMID: 20648473

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

115 results

Results by year